BMY

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 12

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,288

Underlying: Common Stock, $0.10 par value · 21,288 shares

Expires 2027-05-01

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 11

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,134

Underlying: Common Stock, $0.10 par value · 24,134 shares

Expires 2027-01-30

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 10

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,050

Underlying: Common Stock, $0.10 par value · 58,050 shares

Expires 2026-10-31

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 9

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,134

Underlying: Common Stock, $0.10 par value · 24,134 shares

Expires 2026-08-01

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 8

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,003

Underlying: Common Stock, $0.10 par value · 18,003 shares

Expires 2026-05-02

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 7

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,359

Underlying: Common Stock, $0.10 par value · 4,359 shares

Expires 2026-02-01

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 6

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,843

Underlying: Common Stock, $0.10 par value · 5,843 shares

Expires 2025-11-09

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 5

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,843

Underlying: Common Stock, $0.10 par value · 5,843 shares

Expires 2025-07-27

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 4

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,843

Underlying: Common Stock, $0.10 par value · 5,843 shares

Expires 2025-05-04

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · derivative · entry 3

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,794

Underlying: Common Stock, $0.10 par value · 35,794 shares

Expires 2025-02-02

F4 · derivative.exercise_date: All of the shares are currently exercisable. Pursuant to the Merger, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · nonDerivative · entry 2

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Indirect · 401(k)

Disclosed balance after: 613

F3 · shares: Based on a plan statement as of the end of the most recent fiscal quarter.

SEC source: 0000014272-19-000227 · wf-form4_157489451977185.xml · nonDerivative · entry 1

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,178

F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person.

F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 7

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,400

Underlying: Common Stock, $0.10 par value · 47,400 shares

Expires 2022-03-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F10 · derivative.exercise_price: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F8 · derivative.exercise_date: The restricted stock unit vests in full on August 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

F10 · derivative.exercise_date: The restricted stock unit vests in full on March 1, 2022, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 6

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,735

Underlying: Common Stock, $0.10 par value · 73,735 shares

Expires 2022-03-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F9 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F9 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 1, 2020.

SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 5

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,995

Underlying: Common Stock, $0.10 par value · 32,995 shares

Expires 2021-08-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_price: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F8 · derivative.exercise_price: The restricted stock unit vests in full on August 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_date: In connection with the Merger, all outstanding Celgene performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the Merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time), multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement, and (B) the right to receive, immediately upon, and subject to, the vesting of such equity award, one CVR per share per share underlying each such equity award.

F8 · derivative.exercise_date: The restricted stock unit vests in full on August 1, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 4

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,805

Underlying: Common Stock, $0.10 par value · 92,805 shares

Expires 2021-08-01

F5 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on August 1, 2019.

F5 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on August 1, 2019.

SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · derivative · entry 3

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,277

Underlying: Common Stock, $0.10 par value · 193,277 shares

Expires 2028-08-01

F4 · derivative.exercise_date: All of the shares are currently exercisable. Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · nonDerivative · entry 2

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · 401K

Disclosed balance after: 195

F3 · shares: Based on a plan statement as of the end of the most recent fiscal quarter.

SEC source: 0000014272-19-000231 · wf-form4_157489535031849.xml · nonDerivative · entry 1

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,908

F1 · shares: On November 20, 2019 ("Closing Date"), Bristol-Myers Squibb Company ("BMS") completed the previously announced acquisition of Celgene Corporation ("Celgene") contemplated pursuant to the terms and conditions of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), and Celgene. Under the Merger Agreement, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS (the "Merger"). The transactions on this form were not reported in a timely manner due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person.

F2 · shares: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

SEC source: 0000014272-20-000034 · wf-form4a_157810181956331.xml · derivative · entry 2

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,183

Underlying: Common Stock, $0.10 par value · 33,183 shares

Expires 2021-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-20-000034 · wf-form4a_157810181956331.xml · derivative · entry 1

AHMED NADIM · CIK 0001731193 · President, Hematology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,946

Underlying: Common Stock, $0.10 par value · 14,946 shares

Expires 2020-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F2 · derivative.exercise_price: Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person as well as the correct expiration date for a few of the awards.

F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

F5 · derivative.exercise_price: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-20-000035 · wf-form4a_157810184271109.xml · derivative · entry 3

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,401

Underlying: Common Stock, $0.10 par value · 47,401 shares

Expires 2021-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F4 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-20-000035 · wf-form4a_157810184271109.xml · derivative · entry 2

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,624

Underlying: Common Stock, $0.10 par value · 20,624 shares

Expires 2020-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F4 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-20-000035 · wf-form4a_157810184271109.xml · derivative · entry 1

Elkins David V · CIK 0001451604 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,373

Underlying: Common Stock, $0.10 par value · 12,373 shares

Expires 2019-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F2 · derivative.exercise_price: Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person as well as the correct expiration date for a few of the awards.

F3 · derivative.exercise_price: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

F4 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F5 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F4 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F5 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-20-000036 · wf-form4a_157810186432684.xml · derivative · entry 3

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,029

Underlying: Common Stock, $0.10 par value · 45,029 shares

Expires 2021-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F7 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-20-000036 · wf-form4a_157810186432684.xml · derivative · entry 2

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,866

Underlying: Common Stock, $0.10 par value · 25,866 shares

Expires 2020-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F6 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2020, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-20-000036 · wf-form4a_157810186432684.xml · derivative · entry 1

VESSEY RUPERT · CIK 0001677618 · Pres., Research & Early Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,060

Underlying: Common Stock, $0.10 par value · 16,060 shares

Expires 2019-12-31

F1 · derivative.exercise_price: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F2 · derivative.exercise_price: Due to an administrative delay in calculations surrounding the total Merger Consideration (defined below) received by the Reporting Person, this Form 4 is being amended to report the correct number of securities beneficially owned by the Reporting Person as well as the correct expiration date for a few of the awards.

F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_price: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award.

F5 · derivative.exercise_price: Pursuant to the Merger, each outstanding share of Celgene common stock, par value $0.01 per share, was converted into the right to receive (x) $50 in cash, without interest, (y) one share of BMS common stock, par value $0.10 per share and (z) one tradeable contingent value right ( "CVR") per share or, with respect to equity awards (in some cases), per share underlying each such equity award ("Merger Consideration"). Each CVR will represent the right to receive $9.00 in cash upon Federal Drug Administration ("FDA") approval of a specified set of milestones, as set forth in the Contingent Value Rights Agreement, dated as of November 20, 2019, between BMS and Equiniti Trust Company, as trustee.

F1 · derivative.exercise_date: In connection with the merger, all outstanding Celgene Corporation(Celgene) performance share unit awards were assumed by BMS and converted into (A) a restricted unit award that settled in a number of shares of Common Stock equal to the product of (1) the number of Celgene common stock underlying such equity award immediately prior to the merger (with such number of shares determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately preceding the quarter in which the Merger occurs, as determined by the Management Compensation and Development Committee of the board of directors of Celgene prior to the Merger Effective Time),multiplied by (2) the methodology and exchange ratio set forth in the Merger Agreement,and (B) the right to receive, immediately upon,and subject to, the vesting of such equity award, one CVR per share underlying each such equity award.

F3 · derivative.exercise_date: Each restricted stock unit converts into one share of common stock upon vesting.

F4 · derivative.exercise_date: The restricted stock unit vests in full on December 31, 2019, which is the end of the original performance period associated with the original Performance Share Unit award.

SEC source: 0000014272-19-000197 · wf-form4_157307724710649.xml · nonDerivative · entry 1

Elicker John E · CIK 0001554788 · SVP, Public Affairs & IR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,470.583

SEC source: 0000014272-19-000198 · wf-form4_157307726808681.xml · nonDerivative · entry 1

Schmukler Louis S · CIK 0001530894 · Pres., Global Mfg. & Supply

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,963.466

F1 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $56.48 to $56.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000014272-20-000044 · wf-form5_157930085550303.xml · nonDerivative · entry 1

Caforio Giovanni · CIK 0001533201 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 370,884.333

F1 · shares: This transaction involved a donation of securities by the Reporting Person to a charitable organization.

F2 · balance_after: Includes 3,362 shares of common stock that were not previously reported by the Reporting Person due to a clerical error.

SEC source: 0000014272-19-000184 · wf-form4_157013557942143.xml · derivative · entry 3

Biondi Paul · CIK 0001744508 · SVP, Head of Strategy & BD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,184

Underlying: Common Stock, $0.10 par value · 592 shares

Expires 2021-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F1 · shares: Represents vesting of one quarter of restricted stock units granted on October 2, 2017. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date.

F1 · derivative.exercise_date: Represents vesting of one quarter of restricted stock units granted on October 2, 2017. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date.

F1 · derivative.expiration_date: Represents vesting of one quarter of restricted stock units granted on October 2, 2017. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date.

SEC source: 0000014272-19-000184 · wf-form4_157013557942143.xml · nonDerivative · entry 2

Biondi Paul · CIK 0001744508 · SVP, Head of Strategy & BD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,214

F2 · shares: Shares withheld for payment of taxes upon vesting of awards.

SEC source: 0000014272-19-000184 · wf-form4_157013557942143.xml · nonDerivative · entry 1

Biondi Paul · CIK 0001744508 · SVP, Head of Strategy & BD

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,417

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents vesting of one quarter of restricted stock units granted on October 2, 2017. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date.

SEC source: 0000014272-19-000174 · wf-form4_157004943560648.xml · derivative · entry 1

Arduini Peter J · CIK 0001323134 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,312.496

Underlying: Common Stock, $0.10 par value · 714.849 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000175 · wf-form4_157004946408417.xml · derivative · entry 1

BERTOLINI ROBERT J · CIK 0001270263 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,237.429

Underlying: Common Stock, $0.10 par value · 653.224 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000176 · wf-form4_157004948932454.xml · derivative · entry 1

Emmens Matthew · CIK 0001298332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,422.827

Underlying: Common Stock, $0.10 par value · 714.849 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000177 · wf-form4_157004951507319.xml · derivative · entry 1

GROBSTEIN MICHAEL · CIK 0001222342 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,348.574

Underlying: Common Stock, $0.10 par value · 345.1 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000178 · wf-form4_157004953970554.xml · derivative · entry 1

LACY ALAN J · CIK 0001200232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,029.734

Underlying: Common Stock, $0.10 par value · 603.924 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000179 · wf-form4_157004956516903.xml · derivative · entry 1

Paliwal Dinesh C · CIK 0001360224 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,123.479

Underlying: Common Stock, $0.10 par value · 727.174 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000180 · wf-form4_157004959199881.xml · derivative · entry 1

Samuels Theodore R. II · CIK 0001688276 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,055.012

Underlying: Common Stock, $0.10 par value · 603.924 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000181 · wf-form4_157004961733099.xml · derivative · entry 1

Storch Gerald L · CIK 0001205004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,752.653

Underlying: Common Stock, $0.10 par value · 640.899 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000182 · wf-form4_157004964241687.xml · derivative · entry 1

Vousden Karen H · CIK 0001723884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,868.279

Underlying: Common Stock, $0.10 par value · 764.149 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000164 · wf-form4_156763183889624.xml · derivative · entry 3

Santiago Karen Murphy · CIK 0001732137 · Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 642

Underlying: Common Stock, $0.10 par value · 641 shares

Expires 2020-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F1 · shares: Represents vesting of one-quarter of restricted stock units granted on September 1, 2016.

F1 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on September 1, 2016.

F1 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on September 1, 2016.

SEC source: 0000014272-19-000164 · wf-form4_156763183889624.xml · nonDerivative · entry 2

Santiago Karen Murphy · CIK 0001732137 · Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,487

F2 · shares: Shares withheld for payment of taxes upon vesting of awards.

SEC source: 0000014272-19-000164 · wf-form4_156763183889624.xml · nonDerivative · entry 1

Santiago Karen Murphy · CIK 0001732137 · Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,707

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents vesting of one-quarter of restricted stock units granted on September 1, 2016.

SEC source: 0000014272-19-000162 · wf-form4_156469358075770.xml · nonDerivative · entry 1

BERTOLINI ROBERT J · CIK 0001270263 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,397

F1 · shares: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $44.71 to $44.73, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

SEC source: 0000014272-19-000149 · wf-form4_156217532599648.xml · derivative · entry 1

Hirawat Samit · CIK 0001781290 · Chief Medical Offr., Drug Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,425

Underlying: Common Stock, $0.10 par value · 37,425 shares

Expires 2023-07-01

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020.

SEC source: 0000014272-19-000150 · wf-form4_156217534731587.xml · derivative · entry 1

Santiago Karen Murphy · CIK 0001732137 · Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,277

Underlying: Common Stock, $0.10 par value · 4,277 shares

Expires 2023-07-01

F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on July 1, 2020.

SEC source: 0000014272-19-000138 · wf-form4_156210193771325.xml · derivative · entry 1

Arduini Peter J · CIK 0001323134 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,412.492

Underlying: Common Stock, $0.10 par value · 767.536 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

SEC source: 0000014272-19-000139 · wf-form4_156210195577406.xml · derivative · entry 1

BERTOLINI ROBERT J · CIK 0001270263 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,444.114

Underlying: Common Stock, $0.10 par value · 730.43 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.